| Name | Title | Contact Details |
|---|
Genizon BioSciences Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SoundBite Medical is a medical devices company that began operations in May 2015, with its R&D facilities in Sherbrooke and commercialization headquarters in Montreal, Quebec. The Company is developing and commercializing proprietary wire-based device and generator console that delivers safe shockwave energy within the cardiovascular system to treat chronic total occlusions.
BiPar Sciences Incorporated is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
New discoveries are revealing the fundamental role of autophagy and lysosomal flux in maintaining cellular health. Furthermore, it is now appreciated that inadequate or aberrant autophagy contributes to a wide range of diseases. We are focused on boosting autophagy – pioneering novel therapeutic strategies to address unmet medical needs. We are creating a new target set for drug discovery and development, and advancing innovative paradigms to treat a broad set of illnesses that are either neglected or inadequately addressed today. Our growing team is driven to transform fundamental discoveries on autophagy into promising therapeutic medicines.
Immatics Biotechnologies is a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer. Cancer immunotherapy is still severely constrained by the lack of novel targets. Immatics overcomes this by applying its target discovery engine XPRESIDENT® to identify and validate antigens specific to cancer cells. These antigens, also called Tumor-Associated Peptides (TUMAPs), are able to activate T cells which are responsible for identifying and destroying cancer cells. These well characterized TUMAPs can be used as targets for all of the most promising cancer immunotherapy approaches including Adoptive Cell Therapies (ACT), soluble T Cell Receptors (TCRs), Antibodies and Cancer Vaccines. The US based Immatics US, Inc., launched in Aug. 2015, is focused on the development of three ACT approaches for the treatment of tumors with high unmet medical needs: ACTolog™, ACTengine™, and ACTallo™ in close collaboration with leading scientists at the MD Anderson Cancer Center, who contribute their long-term ACT expertise. The first ACT products are expected to enter the clinic in 2016. Immatics signed a strategic cancer immunotherapy collaboration with Roche in November 2013 to research, develop and commercialize a number of new cancer peptide antigen-based immunotherapies. In addition, Immatics is engaged in the development of soluble T-cell receptor (sTCR) approaches as well as monoclonal antibodies (mABs) directed towards XPRESIDENT® targets. The latter will be pursued in a strategic alliance with MorphoSys. Immatics is further conducting the clinical development of fully personalized therapeutic cancer vaccines, Glioma Actively Personalized VAccine Consortium (GAPVAC; an EU-funded consortium) in collaboration with BioNTech. Immatics GmbH is based in Tübingen, Germany, with a headcount of approximately 90 people. Immatics US, Inc. is based in Houston, Texas, USA, and currently employs approximately 15 people.